CareDx, Inc. (NASDAQ:CDNA) Receives $25.00 Average PT from Analysts

Shares of CareDx, Inc. (NASDAQ:CDNA) have been assigned a consensus rating of “Hold” from the six analysts that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, four have given a hold rating and one has issued a buy rating on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $25.00.

Several analysts have weighed in on the stock. Weiss Ratings reaffirmed a “sell (d)” rating on shares of CareDx in a research note on Wednesday, May 27th. BTIG Research upped their price objective on shares of CareDx from $26.00 to $28.00 and gave the stock a “buy” rating in a research note on Wednesday, April 29th. Wall Street Zen raised shares of CareDx from a “buy” rating to a “strong-buy” rating in a research note on Sunday, May 3rd. Finally, Wells Fargo & Company upped their price objective on shares of CareDx from $18.00 to $21.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 25th.

Insider Activity at CareDx

In other news, Director Hannah Valantine sold 12,103 shares of the stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $23.11, for a total transaction of $279,700.33. Following the sale, the director directly owned 36,686 shares of the company’s stock, valued at $847,813.46. This represents a 24.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO John Walter Hanna, Jr. sold 21,998 shares of the stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $24.02, for a total transaction of $528,391.96. Following the sale, the chief executive officer directly owned 649,642 shares in the company, valued at $15,604,400.84. This trade represents a 3.28% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 49,218 shares of company stock worth $1,141,288 over the last three months. 2.40% of the stock is owned by insiders.

Institutional Trading of CareDx

Hedge funds have recently modified their holdings of the stock. Quarry LP bought a new stake in shares of CareDx during the fourth quarter valued at approximately $25,000. FNY Investment Advisers LLC bought a new stake in shares of CareDx during the third quarter valued at approximately $31,000. Meeder Asset Management Inc. bought a new stake in shares of CareDx during the fourth quarter valued at approximately $79,000. Quantbot Technologies LP bought a new stake in shares of CareDx during the third quarter valued at approximately $89,000. Finally, CWM LLC boosted its stake in CareDx by 119.1% in the fourth quarter. CWM LLC now owns 7,407 shares of the company’s stock valued at $140,000 after acquiring an additional 4,026 shares during the last quarter.

CareDx Stock Performance

Shares of CareDx stock opened at $26.18 on Monday. The stock has a market capitalization of $1.35 billion, a price-to-earnings ratio of -163.63 and a beta of 2.49. CareDx has a 1-year low of $10.96 and a 1-year high of $26.26. The firm’s 50-day moving average price is $21.47 and its two-hundred day moving average price is $19.84.

CareDx (NASDAQ:CDNA) last issued its quarterly earnings data on Tuesday, April 28th. The company reported $0.34 earnings per share for the quarter, topping the consensus estimate of $0.11 by $0.23. The firm had revenue of $117.70 million for the quarter, compared to analysts’ expectations of $102.03 million. CareDx had a negative net margin of 2.01% and a negative return on equity of 2.65%. The company’s quarterly revenue was up 39.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.09 earnings per share. As a group, equities research analysts predict that CareDx will post 0.22 EPS for the current year.

About CareDx

CareDx, Inc (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non‐invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post‐transplant journey.

The company’s core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor‐derived cell‐free DNA assay used primarily in kidney transplant monitoring.